-
Who Bears The Brunt Of New Quarantine Costs?
Friday, February 3, 2017 - 4:22pm | 610Read More...The question of how much power the government should exercise to keep Americans safe is a complicated and controversial issue; one that is the root of much of the conflict arising since President Donald Trump took office two weeks ago. Trump’s travel ban on visitors from seven majority-Muslim...
-
NewLink CFO: 'Ebola Vaccine Highly Unlikely To Drive Future Profit In Company'
Friday, December 23, 2016 - 3:54pm | 249Read More...Earlier this morning, the New York Times highlighted an Ebola vaccine that was shown to be 100 percent effective in protecting against the disease. The Ebola vaccine, otherwise known as rVSV-ZEBOV, is currently licensed by Merck & Co., Inc. (NYSE: MRK). Although not yet approved, the New York...
-
Where Does Merck's Ebola Vaccine Breakthrough Leave Competitors?
Friday, December 23, 2016 - 3:38pm | 351Read More...NewLink Genetics Corp (NASDAQ: NLNK) and licensing partner Merck & Co., Inc. (NYSE: MRK) appear to have made a major breakthrough in prevention of one of the deadliest diseases in the world. This week, The Lancet reported 100 percent efficacy in Merck's final-stage trial of an experimental...
-
The Search For Silver Linings In The Cloud Of Negative Novavax News
Monday, September 19, 2016 - 11:35am | 497Read More...It’s hard to find a silver lining following news that sends a stock crashing 84.5 percent in one day. However, following devastating news that the Phase III RESOLVE trial of its RSV vaccine failed to deliver the desired results, Novavax, Inc. (NASDAQ: NVAX) shareholders are looking for any...
-
Raymond James Sees 'Lingering Risks' At OraSure, Downgrades To Market Perform
Monday, June 13, 2016 - 10:11am | 303Read More...Shares of OraSure Technologies, Inc. (NASDAQ: OSUR) are up 20 percent year-to-date. Raymond James’ Nicholas Jansen downgraded the rating for the company from Outperform to Market Perform, saying the shares were within 3 percent of the previous price target of $8. Factors Driving...
-
Chimerix Ditched Its Ebola Treatment To Focus On Cytomegalovirus...And It Just Whiffed Phase 3 Trials
Monday, December 28, 2015 - 10:30am | 280Read More...Chimerix Inc (NASDAQ: CMRX) shares are down more than 77 percent on Monday morning after the company issued a press release that revealed it has missed a primary endpoint on its Phase 3 trial of brincidofovir for patients with cytomegalovirus (CMV) infection. Brincidofovir has been in development...
-
13 Stocks To Watch In The Healthcare Space
Tuesday, October 27, 2015 - 2:38pm | 1881Read More...Healthcare has been one of the best performing sectors of the U.S. stock market for years, but in 2015, shares of healthcare stocks have suffered slightly. Many investors began to worry about the impact next year's presidential election might have on the sector. Some candidates have voiced concern...
-
Sierra Leone's Freetown Set Back In Ebola Eradication
Tuesday, June 23, 2015 - 7:04am | 346Read More...Sierra Leone has recorded two new cases of Ebola in Freetown in the past few days, the first in about three weeks, Reuters reported Monday. The current Ebola epidemic has killed more than 11,000 people in West Africa according to Reuters, about a third of them in Sierra Leone. Liberia became...
-
An Ebola-Fighting Portfolio For The Present And The Future
Friday, June 19, 2015 - 10:04am | 646Read More...Motif Investing looks for “trends, ideas and world events that could create an investment opportunity.” It then selects 10 to 30 stocks related to a particular idea and builds portfolios based on their exposure to it. Fighting Ebola The Ebola scare has been around for a while now...
-
Maxim Analyst Issues Update On Tekmira's Ebola Research Development
Monday, April 13, 2015 - 9:58am | 290Read More...In a report published Monday, Maxim Group analyst Jason Kolbert commented on Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)'s ongoing research into the Ebola virus. Tekmira is part of an international consortium known as the International Severe Acute Respiratory and Emerging Infection Consortium (...
-
Tekmira Back In Vogue After Recent Ebola Outbreak
Tuesday, March 17, 2015 - 12:31pm | 252Read More...Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. Tekmira Pharmaceuticals Corp (NASDAQ: TKMR) shares were trading sharply higher by $1.62 (9 percent) at $20.06 in Tuesday's session. The catalyst for the rally has been the outbreak of 21 new Ebola cases...
-
World Health Organization Approves Corgenix's Ebola Test, Shares Spike Higher
Friday, February 20, 2015 - 12:19pm | 121Read More...Shares of Corgenix Medical Corporation (OTC: CONX) spiked higher by more than 7 percent on Friday after the World Health Organization approved the company's 15-minute Ebola test. Corgenix Medical's Ebola test is less accurate than the standard PCR test, but is easy to perform, does not require...
-
Tekmira Pharmaceuticals, Lakeland Industries Moving On Possible Ebola Case In California
Thursday, January 29, 2015 - 3:44pm | 254Read More...Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR) and Lakeland Industries, Inc.'s (NASDAQ: LAKE) shares were on the move Thursday afternoon, reacting to the news of a patient being treated for possible Ebola symptoms in Sacramento County, California. According to Dignity Health, the...
-
Health Care And Biotech Sector Looking Sick
Tuesday, December 23, 2014 - 4:42pm | 834Read More...As the broad market charges to new all-time highs, not all stocks and sectors are participating. Two sectors that are going in the exact opposite directions of the market are issues in the healthcare sector and biotech sector. Free-Falling Now The charts of the iShares NASDAQ Biotechnology...
-
Sheryl Sandberg On Facebook's Biggest Moment Of 2014
Wednesday, December 17, 2014 - 3:30pm | 385Read More...Times have changed. To gauge the impact created by events is easy -- find out is what's trending on social media. Facebook Inc (NASDAQ: FB) released its biggest moments of 2014 on Tuesday morning, which is a list of top 10 moments across the globe and the most-talked about things and people...
